A European Commission decision on belzutifan plus lenvatinib in pretreated advanced ccRCC is expected within 2 months, based on LITESPARK-011 data.
Commentary|Articles|February 10, 2025
Supplements and Featured Publications
- Perspectives on FDA Oncology Approvals and Withdrawals That Shaped 2024: A Year in Review Roundup
- Volume 1
- Issue 1
Experts Comment on the GI/GU Cancer FDA Approvals From 2024
Author(s)Megan Hollasch
Fact checked by: Caroline Seymour
Experts provide insights on the 2024 FDA approvals in the gastrointestinal and genitourinary fields in this list featuring all the regulatory decisions.
Advertisement
Advertisement
The gastrointestinal (GI) and genitourinary (GU) fields saw over 10 FDA approvals add to their paradigms in 2024, and throughout the year oncologists sat down with OncLive to detail the significance of these regulatory decisions.
Related to this article
Age, geographic location, transportation barriers, and language and communication barriers may limit patient opportunities to participate in research.
Check out this October recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
Thomas Powles, MBBS, MRCP, MD, discusses LITESPARK-022 QOL findings and patient selection for adjuvant belzutifan plus pembrolizumab in RCC.
Retrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.
Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.
Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
Advertisement
Advertisement